bioRxiv · 10.1101/2020.03.20.999326
Development of Nanobodies as first-in-class inhibitors for the NEDP1 deNEDDylating enzyme
Abstract
Protein NEDDylation emerges as an important post-translational modification and an attractive target for therapeutic intervention. Modification of NEDD8 onto substrates is finely balanced by the co-ordinated activity of conjugating and deconjugating enzymes. The NEDP1/DEN1/SENP8 protease is a NEDD8 specific processing and deconjugating enzyme that regulates the NEDDylation mainly of non-cullin substrates. Here, we report the development and characterisation of nanobodies as first-in-class inhibitors for NEDP1. The nanobodies display high-affinity (low nM) against NEDP1 and specifically inhibit NEDP1 processing activity in vitro and NEDP1 deconjugating activity in tissue-culture cells and in cell extracts. We also isolated nanobodies that bind to NEDP1 with high-affinity but do not affect NEDP1 activity. The developed nanobodies provide new tools to study the function of NEDP1 and to prevent deNEDDylation in cell extracts used in biochemical assays.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Xirodimas, D., Abidi, N., Pugniere, M., Muyldermans, S., Trauchessec, H.. 2020-03-22. Development of Nanobodies as first-in-class inhibitors for the NEDP1 deNEDDylating enzyme. https://doi.org/10.1101/2020.03.20.999326
Cite the original work for its findings. Save a collection to share your selection of sources.